A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
NCT ID: NCT00734474 Phase: PHASE2 Status: COMPLETED Enrollment: 1202 Completion: 2012-07
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Sitagliptin, Placebo solution, Placebo tablet, Metformin
Summary
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
Primary Outcome
Glycosylated Hemoglobin (HbA1c) Change From Baseline